Tue, Jul 22, 2014, 11:12 AM EDT - U.S. Markets close in 4 hrs 48 mins

Recent

% | $
Click the to save as a favorite.

Neurocrine Biosciences Inc. Message Board

  • dvnetter dvnetter Nov 22, 1999 7:56 PM Flag

    Hard to believe....

    This stock has a tremendous week, last week and
    even better day today....and the activity on this
    board is so lame....we can definitely do better than
    this..RIGHT!!!!! We are on the brink of a breakthrough and we have
    not even broken the 800 mark on messages..where are
    you folks?

    LONG AND STRONG since 1997-----

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • will come one after another which means more good news are in the pipeline. The stock price will jump and jump like a rabit.

    • Unlike Zoloft and Prozac, NBIX's R121919 blocks
      CRF receptors downstream and has no action on
      serotonin. So no sexual dysfunction associated with the
      drug, and the central effects are more rapid in onset.
      This advantage could easily blow Prozac and Zoloft
      away because people prefer quick effect and enjoy sex.

    • Neurocrine co-founder Dr. Wylie Vale is a recognized leader in CRF work and a star in neuroscience. They have a first class team working on this area and have teamed up with Janssen on the project.

    • Neurocrine holds the leadership position with
      this novel technology with US patent rights to all
      known CRF Receptors and CRF Binding Proteins.


      Source: http://www.neurocrine.com/research/research.html

    • On November 29(Monday), NBIX will report the
      preliminary results from clinical trials of its novel
      insomnia and anxiety/depression compounds.

      Both
      compounds are aimed at markets at or above $1 billion and
      are poorly served by current
      treatments.

      Insomnia affects 30-40% of Americans and is a $1 billion
      market. Neurocrine has developed a compound that is
      superior to existing drugs such as Ambien (controls 80% of
      the market) and Sonata (the newest sleep drug)), as
      it is more selective (reducing side-effect profile),
      has less abuse potential, has a reduced tendency to
      �potentiate� the effects of alcohol and it is more potent.


      With respect to anxiety and depression, encouraging
      early results of clinical trials with Neurocrine�s CRF
      receptor antagonist for depression has led Janssen
      Pharmaceutica to expand its collaboration to further develop
      this class of compounds.

      NBIX scientists use a
      novel approach (CRF receptors) to treat depression
      (very different from the neural pathways targeted by
      the benzodiazepines (Valium) or SSRIs (Prozac,
      Zoloft). Based on preliminary clinical data, R121919 acts
      quickly, it is not addictive and does not cause sexual
      dysfunction.

      The potential of the CRF program is as large as any
      blockbuster drug ever.

      There is no doubt Big Pharmas
      will compete to acquire it.

    • I agree with you and expect many surging waves
      ahead. Any minor pull-backs(daily flactuation) between
      these surging waves should be great buying
      opportunities. There is no reason to expect a major pull-back
      right now. So many positives are ahead and the stock
      price is still well undervalued comparing to its peers.

    • There probably will not be any pullback b/c
      analysts usually add premiums to share prices the more
      liscensing and marketing deals that biotechs acquire.
      Therefore NBIX will probably find someone to co-market the
      insomnia drug and the anti-depressant should start getting
      more press. That's my take...

    • "- NBIX has price potential for 50 in 2000 and
      100 in 2001, based on NDAs for 2+ compounds, and
      assuming Big Pharma doesn't try a hostile buyout before
      then."

      Woodie_UK, I agree with your price target and your detailed
      reasoning.

    • Your quote:
      NBIX has price potential for 50 in
      2000 and 100 in 2001, based on NDAs for 2+ compounds,
      and assuming Big Pharma doesn't try a hostile buyout
      before then.

      Woodie, do you expect a bid war from
      Big Pharmas?

    • They'll get squashed like bugs on the next burst
      of institutional buying!! I'm not sure these
      characters actually have done any DD on NBIX... They see it
      up 32% one day, and just assume it's a good short
      candidate. Oops! NOT!!

    • View More Messages
 
NBIX
13.53+0.36(+2.70%)11:11 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.